Novel EV71 virus strain and application thereof

Abstract

The invention discloses a novel EV71 virus strain of which the whole-genome length is 7405bp and the sequence is shown in SEQID NO:1. The virus strain can infect ICR, KM, BALB / c and NIH mice; the virus dosage of larger than 1*10<2>-1*10<7> TCID50 can cause the disease attack or death of 1-17 days mice; the administration route can be intraperitoneal injection, encephalocoele injection and intragastric administration; the symptoms are typical symptoms of EV71 virus infection and are divided into the following five levels according to stages of the disease: Level 0: not attacked; L1: motion incoordination and weakness of limbs; L2: hypokinesia and paralysis of fore or posterior limbs; L3: quadriplegia and dying; and L4: death. Various animal evaluation models such as an immunogenicity animal evaluation model of hand-foot-and-mouth disease vaccine and an animal evaluation model of EV71 therapeutic drug and therapeutic vaccine, can be built conveniently.

Description

Technical field [0001] The invention relates to a new type of EV71 virus and its application. Background technique [0002] Epidemiology [0003] Hand, foot and mouth disease is a global infectious disease. The epidemic has been reported in most parts of the world. It was first described by Seddon of New Zealand in 1957. In 1974, Schmidt first isolated and identified EV71 from a stool sample of a child with a brain (1969). In the following 3 years, the virus was again isolated from 23 patients with severe nervous system in California. And then the disease has a broader spectrum of changes, with symptoms ranging from fever, hand-foot-mouth disease, herpes, aseptic meningitis, paralysis, encephalitis, and even death. [0004] In 1975, more than 750 people in Bulgaria became ill, and 44 of them died. [0005] In 1978, a large-scale epidemic occurred in Japan. A total of 36,301 cases were found. Except for a few aseptic meningitis, the main manifestation was HFMD. [0006] After 1997, th...

AI Technical Summary

Problems solved by technology

However, the mortality rate of the treatment group still reached 70%, indicating that the in vivo treatment effect is weak

[0034] At present, there are no effective animal infection models and immune protection models for HFMD vaccines, and it is impossible to accurately evaluate the immunogenicity of HFMD vaccines and the therapeutic effect of HFMD

Images